First detection of a <i>Mycobacterium tuberculosis</i> XDR clinical isolate harbouring an RpoB I491F mutation in a Ukrainian patient treated in Germany, October 2023
Friesen I, Dreyer V, Klingmüller A, Zuber S, Hoffmann AM, Suárez I, Schütz B, Preßel T, et al. (11 authors)
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024-07
Abstract
This report documents the case of a Ukrainian patient infected with an extensively drug-resistant (XDR) lineage 2 Mycobacterium tuberculosis strain harbouring the rifampicin resistance mutation RpoB I491F. This mutation is not detected by routine molecular WHO-recommended rapid diagnostics, complicating the detection and treatment of these strains. The occurrence of such mutations underscores the need for enhanced diagnostic techniques and tailored treatment regimens, especially in eastern Europe where lineage 2 strains and XDR-tuberculosis are prevalent.
MeSH terms
- Humans
- Mycobacterium tuberculosis
- Rifampin
- DNA-Directed RNA Polymerases
- Bacterial Proteins
- Antitubercular Agents
- Microbial Sensitivity Tests
- Mutation
- Adult
- Ukraine
- Germany
- Female
- Extensively Drug-Resistant Tuberculosis